Jazz Pharmaceuticals plc SVP and Chief Accounting Officer Patricia Carr filed a Form 4 on November 6, 2026, disclosing transactions in ordinary shares on November 4, 2026, including an option exercise and two open-market sales.

Key Highlights

  • Option exercise: Carr exercised 1,250 non-qualified stock options at an exercise price of $140.03 per share on November 4, 2026, acquiring 1,250 ordinary shares.
  • Sale at $231.37: Carr disposed of 1,250 ordinary shares at $231.37 per share on November 4, 2026.
  • Sale at $231.27: Carr disposed of an additional 163 ordinary shares at $231.27 per share on November 4, 2026.
  • Remaining beneficial ownership: Following all reported transactions, Carr directly owned 6,512 ordinary shares.
  • Remaining options: Carr held 3,000 non-qualified stock options following the reported exercise.
  • ESPP shares: The 163 shares sold were acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2026, according to the filing.

Patricia Carr's November 4 Option Exercise and Share Sales at Jazz Pharmaceuticals

According to the Form 4 filed with the SEC on November 6, 2026, Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), reported three transactions in ordinary shares, all dated November 4, 2026. The filing was signed by Paz Dizon as attorney in fact for Patricia Carr.

The filing discloses that Carr exercised 1,250 non-qualified stock options at a conversion or exercise price of $140.03 per ordinary share, acquiring 1,250 shares via transaction code M. The filing states these options were granted under the issuer's 2011 Equity Incentive Plan, with a grant date of February 28, 2019, vesting over four years with one-quarter vesting on the first anniversary and the remainder vesting in 36 equal monthly installments thereafter. The options carry an expiration date of February 27, 2029. The price of the derivative security at exercise is listed as $0.0 in the filing.

On the same date, Carr disposed of 1,250 ordinary shares at $231.37 per share and an additional 163 ordinary shares at $231.27 per share. The filing notes that the 163 shares were originally acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2026. After all reported transactions, Carr's direct beneficial ownership stood at 6,512 ordinary shares, with 3,000 non-qualified stock options remaining, the filing states.

What Was Disclosed

The filing reports an option exercise of 1,250 shares at $140.03 and two sales totaling 1,413 ordinary shares at prices of $231.37 and $231.27 by Jazz Pharmaceuticals' Chief Accounting Officer on November 4, 2026, leaving her with 6,512 shares directly owned.